Search Results | American Association for Cancer Research

1-20 of 205

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies

Yimei Li, Wei-Ting Hwang, Shannon L. Maude, David T. Teachey, Noelle V. Frey, Regina M. Myers, Allison Barz Leahy, Hongyan Liu, David L. Porter, Stephan A. Grupp, Pamela A. Shaw

Clin Cancer Res (2022) 28 (18): 3940–3949.

DOI: https://doi.org/10.1158/1078-0432.CCR-22-0560

Published: 15 September 2022

View article

Includes: Supplementary data

Journal Articles

Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies

Grace Collins, Mark Stewart, Brittany McKelvey, Hillary Stires, Jeff Allen

Clin Cancer Res OF1–OF4.

DOI: https://doi.org/10.1158/1078-0432.CCR-22-0983

Published: 27 June 2022

View article

Includes: Supplementary data

Journal Articles

Report of the First International Symposium on NUT Carcinoma

Clin Cancer Res (2022) 28 (12): 2493–2505.

DOI: https://doi.org/10.1158/1078-0432.CCR-22-0591

Published: 13 June 2022

View article

Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Clin Cancer Res (2022) 28 (5): 831–839.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3238

Published: 03 March 2022

View article

Journal Articles

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020

Bhakti Arondekar, Mei Sheng Duh, Rachel H. Bhak, Maral DerSarkissian, Lynn Huynh, Kelsey Wang, John Wojciehowski, Melody Wu, Bryon Wornson, Alexander Niyazov, George D. Demetri

Clin Cancer Res (2022) 28 (1): 27–35.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-2639

Published: 01 January 2022

View article

Includes: Supplementary data

Journal Articles

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Phaedon D. Zavras, Aditi Shastri, Mendel Goldfinger, Amit K. Verma, Yogen Saunthararajah

Clin Cancer Res (2021) 27 (24): 6653–6661.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-2139

Published: 15 December 2021

View article

Journal Articles

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Stefanie L. Groenland, Remy B. Verheijen, Markus Joerger, Ron H.J. Mathijssen, Alex Sparreboom, Jos H. Beijnen, Jan H. Beumer, Neeltje Steeghs, Alwin D.R. Huitema

Clin Cancer Res (2021) 27 (24): 6644–6652.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4555

Published: 15 December 2021

View article

Journal Articles

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade

Laura S. Graham, Colin C. Pritchard, Michael T. Schweizer

Clin Cancer Res (2021) 27 (24): 6662–6665.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3031

Published: 15 December 2021

View article

Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Clin Cancer Res (2022) 28 (4): 603–608.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1237

Published: 17 November 2021

View article

Journal Articles

MRN Complex and Cancer Risk: Old Bottles, New Wine

Islam E. Elkholi, William D. Foulkes, Barbara Rivera

Clin Cancer Res (2021) 27 (20): 5465–5471.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1509

Published: 15 October 2021

View article

Journal Articles

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Clin Cancer Res (2021) 27 (19): 5195–5212.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1059

Published: 01 October 2021

View article

Journal Articles

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

David A. Potter, Alexandra Thomas, Hope S. Rugo

Clin Cancer Res (2021) 27 (16): 4486–4490.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1133

Published: 15 August 2021

View article

Journal Articles

Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer

Kim A. Reiss, Robert H. Vonderheide

Clin Cancer Res (2021) 27 (13): 3540–3542.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0612

Published: 01 July 2021

View article

Journal Articles

High-Specific-Activity-¹³¹I-MIBG versus ¹⁷⁷Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Clin Cancer Res (2021) 27 (11): 2989–2995.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3703

Published: 01 June 2021

View article

Journal Articles

Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer

Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain

Clin Cancer Res (2021) 27 (10): 2706–2711.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4750

Published: 15 May 2021

View article

Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

R. Donald Harvey, Kathryn F. Mileham, Vishal Bhatnagar, Jamie R. Brewer, Atiqur Rahman, Cassadie Moravek, Andrew S. Kennedy, Elizabeth A. Ness, E. Claire Dees, S. Percy Ivy, Scot W. Ebbinghaus, Caroline Schenkel, Thomas S. Uldrick

Clin Cancer Res (2021) 27 (9): 2400–2407.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3855

Published: 01 May 2021

View article

Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, Brad Hirsch, Allen Melemed, Fernanda I. Arnaldez, Upal Basu Roy, Caroline Schenkel, Shimere Sherwood, Elizabeth Garrett-Mayer

Clin Cancer Res (2021) 27 (9): 2424–2429.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3868

Published: 01 May 2021

View article

Journal Articles

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett-Mayer, Whitney Rhodes, Edward Stepanski, Thomas S. Uldrick, Gwynn Ison, Sean Khozin, Wendy S. Rubinstein, Caroline Schenkel, Robert S. Miller, George A. Komatsoulis, Richard L. Schilsky, Edward S. Kim

Clin Cancer Res (2021) 27 (9): 2430–2434.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3857

Published: 01 May 2021

View article

Includes: Supplementary data

Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Alexander I. Spira, Mark D. Stewart, Suzanne Jones, Elaine Chang, Anitra Fielding, Nicole Richie, Laura S. Wood, Michael A. Thompson, Lee Jones, Abhilasha Nair, Brandon A. Mahal, David E. Gerber

Clin Cancer Res (2021) 27 (9): 2416–2423.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3853

Published: 01 May 2021

View article

Includes: Supplementary data

Journal Articles

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, Madison M. Wempe, Richard L. Schilsky, Edward S. Kim, James L. Wade, III

Clin Cancer Res (2021) 27 (9): 2408–2415.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3854

Published: 01 May 2021

View article

2 3 4 5

NARROW

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies

Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies

Report of the First International Symposium on NUT Carcinoma

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

MRN Complex and Cancer Risk: Old Bottles, New Wine

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer

High-Specific-Activity-¹³¹I-MIBG versus ¹⁷⁷Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

AACR Journals

AACR Journals

This Feature Is Available To Subscribers Only